Premium
Pembrolizumab for the treatment of programmed death–ligand 1‒positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE‐028 study
Author(s) -
Mehnert Janice M.,
Bergsland Emily,
O’Neil Bert H.,
Santoro Armando,
Schellens Jan H. M.,
Cohen Roger B.,
Doi Toshihiko,
Ott Patrick A.,
Pishvaian Michael J.,
Puzanov Igor,
Aung Kyaw L.,
Hsu Chiun,
Le Tourneau Christophe,
Hollebecque Antoine,
Élez Elena,
Tamura Kenji,
Gould Marlena,
Yang Ping,
Stein Karen,
PihaPaul Sarina A.
Publication year - 2020
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.32883
Subject(s) - medicine , pembrolizumab , cohort , neuroendocrine tumors , clinical endpoint , gastroenterology , oncology , cancer , immunotherapy , clinical trial
Background Despite a protracted disease course and multiple available therapies, patients with well‐differentiated neuroendocrine tumors (NETs) inevitably experience disease progression. Programmed death–ligand 1 (PD‐L1) has been associated with NET progression and prognosis. The multicohort, phase 1 KEYNOTE‐028 study (ClinicalTrials.gov identifier NCT02054806) evaluated the activity and safety of the anti–programmed cell death protein 1 immunotherapy pembrolizumab in patients with well‐differentiated or moderately‐differentiated NETs. Methods Patients with PD‐L1–positive, locally advanced or metastatic carcinoid or well–differentiated or moderately‐differentiated pancreatic NETs (pNETs) were enrolled into separate cohorts and received pembrolizumab at a dose of 10 mg/kg every 2 weeks for up to 2 years. The objective response rate was the primary endpoint (as per Response Evaluation Criteria in Solid Tumors version 1.1, by investigator review). Safety was a secondary endpoint. Results Of 170 and 106 patients, respectively, who had evaluable samples among those screened for the carcinoid and pNET cohorts, 21% and 25%, respectively, had PD‐L1–positive tumors; of these, 25 and 16 patients, respectively, were eligible and treated. The median follow‐up was 20 months (range, 2‐35 months) and 21 months (range, 5‐32 months), respectively. The objective response rate was 12.0% (95% CI, 2.5%‐31.2%) and 6.3% (95% CI, 0.2%‐30.2%), respectively; 3 partial responses occurred among the carcinoid cohort and 1 among the pNET cohort. The median duration of response in the carcinoid cohort was 9.2 months (range, 6.9‐11.1 months), and was not reached in the pNET cohort. No complete responses occurred. Treatment‐related adverse events occurred in 68% and 69% of patients, respectively, most often diarrhea (7 patients in the carcinoid cohort and 4 patients in the pNET cohort) and fatigue (6 patients in each cohort). Hypothyroidism was the most common immune‐mediated adverse event (5 patients in the carcinoid cohort and 2 patients in the pNET cohort). Conclusions Pembrolizumab demonstrated antitumor activity in a subset of patients with NETs and was well‐tolerated.